URGN Q1 2019 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$22M

Operating Income

-$22M

Net Income

-$21M

EPS (Diluted)

$-1.11

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$252M

Total Liabilities

$12M

Stockholders' Equity

$240M

Cash & Equivalents

$247M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$481,000	-100.0%
Gross Profit	-$22M	$51,000	-44086.3%
Operating Income	-$22M	-$14M	-64.5%
Net Income	-$21M	-$13M	-60.2%